Compare Johnson & Johnson (JNJ) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs PAGSEG Inc — how do they compare? Johnson & Johnson trades at $249.3 (market cap $598.96B), while PAGSEG Inc trades at $9.55 (market cap $2.60B). The key difference: Johnson & Johnson is far larger — about 230.4× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.19%). Which is the better fit depends on your goals.
| JNJ | PAGS | |
|---|---|---|
Market Cap | $598.96B | $2.60B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $12.00 |
52-Week Low | $164.36 | $7.75 |
Enterprise Value | $631.90B | $10.23B |
Dividend Yield | 2.15% | 11.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
PAGS trades at $9.29, up 2.77% today, with bearish technical signals but strong fundamentals including a P/E of 6.4 and net income margin of 10.4%. Recent earnings showed a Q1 2026 miss at $0.39 EPS versus $0.40 expected, while Q4 2025 beat expectations. The company maintains robust cash flow from operations of $7.56B in 2025 and declared a $0.26 dividend for H1 2026, payable June 1, 2026.
The stock presents a value opportunity with low valuation multiples and solid profitability, though technical weakness and mixed earnings create near-term uncertainty. Risks include Brazilian macroeconomic sensitivity and competitive pressures, but analyst consensus is strongly bullish with 62.5% buy ratings, suggesting upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
